Opus Genetics (IRD) Shares Outstanding (Diluted Average) (2016 - 2026)

Opus Genetics (IRD) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $86.9 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $86.9 million, up 156.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.9 million (up 156.43% YoY), and the FY2025 annual result was $62.2 million, up 132.91% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $86.9 million in Q1 2026 per IRD's latest filing, from $62.2 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $86.9 million in Q1 2026 and troughed at $18.9 million in Q1 2022.
• A 5-year average of $35.1 million and a median of $25.8 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) grew 9.13% in 2023, then surged 170.17% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $19.6 million in 2022, then gained by 9.95% to $21.6 million in 2023, then advanced by 23.74% to $26.7 million in 2024, then surged by 132.91% to $62.2 million in 2025, then jumped by 39.65% to $86.9 million in 2026.
• Business Quant data shows IRD's Shares Outstanding (Diluted Average) at $86.9 million in Q1 2026, $62.2 million in Q4 2025, and $70.6 million in Q3 2025.